1. Market Research
  2. > Gram-Positive Bacterial Infections - Pipeline Review, H2 2013

Gram-Positive Bacterial Infections - Pipeline Review, H2 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 189 pages

Gram-Positive Bacterial Infections - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Gram-Positive Bacterial Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Gram-Positive Bacterial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gram-Positive Bacterial Infections. Gram-Positive Bacterial Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Gram-Positive Bacterial Infections.
- A review of the Gram-Positive Bacterial Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Gram-Positive Bacterial Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Gram-Positive Bacterial Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Gram-Positive Bacterial Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Gram-Positive Bacterial Infections - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Gram-Positive Bacterial Infections Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Gram-Positive Bacterial Infections 9
Gram-Positive Bacterial Infections Therapeutics under Development by Companies 11
Gram-Positive Bacterial Infections Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Gram-Positive Bacterial Infections Therapeutics - Products under Development by Companies 20
Gram-Positive Bacterial Infections Therapeutics - Products under Investigation by Universities/Institutes 23
Companies Involved in Gram-Positive Bacterial Infections Therapeutics Development 24
Rib-X Pharmaceuticals, Inc. 24
Aphios Corporation 25
BioMarin Pharmaceutical Inc. 26
Alchemia Limited 27
Immtech Pharmaceuticals, Inc. 28
Basilea Pharmaceutica Ltd. 29
Oragenics, Inc. 30
Dongwha Pharm Co., Ltd. 31
Theravance, Inc. 32
Phynova Group Ltd 33
Novabiotics Ltd 34
Priaxon AG 35
ConjuGon, Inc. 36
MicuRx Pharmaceuticals, Inc. 37
AiCuris GmbH and Co. KG 38
Destiny Pharma Ltd. 39
Atox Bio Inc. 40
Microbiotix, Inc. 41
Cellceutix Corporation 42
KYORIN Pharmaceutical Co., Ltd. 44
Lytix Biopharma AS 45
TAXIS Pharmaceuticals, Inc. 46
Aureogen Biosciences, Inc. 47
Cantab Biopharmaceuticals Limited 48
Gram-Positive Bacterial Infections - Therapeutics Assessment 49
Assessment by Monotherapy Products 49
Assessment by Combination Products 50
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 55
PYN-6 - Drug Profile 55
LT-29 - Drug Profile 56
MX-2401 - Drug Profile 57
TD-1792 - Drug Profile 58
Antibiotic Program - Drug Profile 60
MU-1140 - Drug Profile 61
RX-04 - Drug Profile 63
RX-02 - Drug Profile 64
NVB-333 - Drug Profile 65
zabofloxacin - Drug Profile 66
LTX-109 - Drug Profile 68
Marinus - Drug Profile 70
AB-103 - Drug Profile 71
avarofloxacin hydrochloride - Drug Profile 73
ceftobiprole - Drug Profile 76
Hybrid Antibiotics - Drug Profile 79
Antibiotic Program - Drug Profile 80
SLP-0905 - Drug Profile 81
SLP-0906 - Drug Profile 82
SLP-1003 - Drug Profile 83
SLP-0904 - Drug Profile 84
SLP-1004 - Drug Profile 85
BAC Gram -/+ - Drug Profile 86
KRPAM-1977X - Drug Profile 87
KRPAM-1977Y - Drug Profile 88
RX-P792 - Drug Profile 89
Novarifyn - Drug Profile 91
Drug For Gram Positive Wound Infections - Drug Profile 92
MBX-500 - Drug Profile 93
MU-1140-S - Drug Profile 94
3-(4-chlorophenyl)-4-Substituted Pyrazole Derivatives - Drug Profile 96
NAI-107 - Drug Profile 97
Azachryseniums Series - Drug Profile 98
XF-70 - Drug Profile 99
PC-190723 - Drug Profile 100
PBP-539 - Drug Profile 101
Thiolactomycin Analogues - Drug Profile 102
SP-2078 - Drug Profile 103
Sortase A Enzyme Inhibitor - Drug Profile 104
Antibacterial Compounds For Gram Possitive Bacterial Infections - Drug Profile 105
TD-1607 - Drug Profile 106
Ripostatin - Drug Profile 107
Drug For Gram-Positive Bacterial Infections - Drug Profile 108
Broad-Spectrum Antibiotics Targeting Switch Region - Drug Profile 109
Broad-Spectrum Antibiotics Targeting RNA-Exit-Channel - Drug Profile 110
VT-02 - Drug Profile 111
Antibiotic Compounds - Drug Profile 112
PMX-100 - Drug Profile 113
PMX-229 - Drug Profile 114
PMX-519 - Drug Profile 115
PMX-1091 - Drug Profile 117
PMX-1142 - Drug Profile 118
PMX-1241 - Drug Profile 119
PMX-1442 - Drug Profile 120
PMX-1445 - Drug Profile 121
PMX-1555 - Drug Profile 122
PMX-868 - Drug Profile 123
PMX-1090 - Drug Profile 124
PMX-223 - Drug Profile 125
PMX-225 - Drug Profile 126
PMX-1363 - Drug Profile 127
PMX-1405 - Drug Profile 128
PMX-183 - Drug Profile 129
NOSO-95 - Drug Profile 130
NOSO-74 - Drug Profile 131
Compound-45 - Drug Profile 132
BMY-28117 - Drug Profile 133
Gamma AApeptides - Drug Profile 134
PMX-1099 - Drug Profile 135
PMX-843 - Drug Profile 136
PMX-1102 - Drug Profile 137
PMX-1014 - Drug Profile 138
PMX-0196 - Drug Profile 139
PMX-1045 - Drug Profile 140
PMX-1056 - Drug Profile 141
PMX-1057 - Drug Profile 142
PMX-1094 - Drug Profile 143
PMX-0243 - Drug Profile 144
PMX-0231 - Drug Profile 146
PMX-255 - Drug Profile 148
PMX-520 - Drug Profile 149
PMX-728 - Drug Profile 150
PMX-741 - Drug Profile 151
Broad Spectrum Antimicrobials - Drug Profile 152
Gram-Positive Bacterial Infections Therapeutics - Drug Profile Updates 153
Gram-Positive Bacterial Infections Therapeutics - Discontinued Products 171
Gram-Positive Bacterial Infections Therapeutics - Dormant Products 172
Gram-Positive Bacterial Infections - Product Development Milestones 174
Featured News and Press Releases 174
Appendix 182
Methodology 182
Coverage 182
Secondary Research 182
Primary Research 182
Expert Panel Validation 182
Contact Us 183
Disclaimer 183



List of Tables

Number of Products Under Development for Gram-Positive Bacterial Infections, H2 2013 15
Products under Development for Gram-Positive Bacterial Infections - Comparative Analysis, H2 2013 16
Number of Products under Development by Companies, H2 2013 18
Number of Products under Development by Companies, H2 2013 (Contd..1) 19
Number of Products under Investigation by Universities/Institutes, H2 2013 21
Comparative Analysis by Late Stage Development, H2 2013 22
Comparative Analysis by Mid Clinical Stage Development, H2 2013 23
Comparative Analysis by Early Clinical Stage Development, H2 2013 24
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 25
Products under Development by Companies, H2 2013 26
Products under Development by Companies, H2 2013 (Contd..1) 27
Products under Development by Companies, H2 2013 (Contd..2) 28
Products under Investigation by Universities/Institutes, H2 2013 29
Rib-X Pharmaceuticals, Inc., H2 2013 30
Aphios Corporation, H2 2013 31
BioMarin Pharmaceutical Inc., H2 2013 32
Alchemia Limited, H2 2013 33
Immtech Pharmaceuticals, Inc., H2 2013 34
Basilea Pharmaceutica Ltd., H2 2013 35
Oragenics, Inc., H2 2013 36
Dongwha Pharm Co., Ltd., H2 2013 37
Theravance, Inc., H2 2013 38
Phynova Group Ltd, H2 2013 39
Novabiotics Ltd, H2 2013 40
Priaxon AG, H2 2013 41
ConjuGon, Inc., H2 2013 42
MicuRx Pharmaceuticals, Inc., H2 2013 43
AiCuris GmbH and Co. KG, H2 2013 44
Destiny Pharma Ltd., H2 2013 45
Atox Bio Inc., H2 2013 46
Microbiotix, Inc., H2 2013 47
Cellceutix Corporation, H2 2013 48
KYORIN Pharmaceutical Co., Ltd., H2 2013 50
Lytix Biopharma AS, H2 2013 51
TAXIS Pharmaceuticals, Inc., H2 2013 52
Aureogen Biosciences, Inc., H2 2013 53
Cantab Biopharmaceuticals Limited, H2 2013 54
Assessment by Monotherapy Products, H2 2013 55
Assessment by Combination Products, H2 2013 56
Assessment by Stage and Route of Administration, H2 2013 58
Assessment by Stage and Molecule Type, H2 2013 60
Gram-Positive Bacterial Infections Therapeutics - Drug Profile Updates 159
Gram-Positive Bacterial Infections Therapeutics - Discontinued Products 177
Gram-Positive Bacterial Infections Therapeutics - Dormant Products 178
Gram-Positive Bacterial Infections Therapeutics - Dormant Products (Contd..1) 179



List of Figures

Number of Products under Development for Gram-Positive Bacterial Infections, H2 2013 15
Products under Development for Gram-Positive Bacterial Infections - Comparative Analysis, H2 2013 16
Products under Development by Companies, H2 2013 17
Products under Investigation by Universities/Institutes, H2 2013 20
Late Stage Products, H2 2013 22
Mid Clinical Stage Products, H2 2013 23
Early Clinical Stage Products, H2 2013 24
Discovery and Pre-Clinical Stage Products, H2 2013 25
Assessment by Monotherapy Products, H2 2013 55
Assessment by Combination Products, H2 2013 56
Assessment by Route of Administration, H2 2013 57
Assessment by Stage and Route of Administration, H2 2013 58
Assessment by Molecule Type, H2 2013 59
Assessment by Stage and Molecule Type, H2 2013 60



Companies Mentioned

Rib-X Pharmaceuticals, Inc.
Aphios Corporation
BioMarin Pharmaceutical Inc.
Alchemia Limited
Immtech Pharmaceuticals, Inc.
Basilea Pharmaceutica Ltd.
Oragenics, Inc.
Dongwha Pharm Co., Ltd.
Theravance, Inc.
Phynova Group Ltd
Novabiotics Ltd
Priaxon AG
ConjuGon, Inc.
MicuRx Pharmaceuticals, Inc.
AiCuris GmbH and Co. KG
Destiny Pharma Ltd.
Atox Bio Inc.
Microbiotix, Inc.
Cellceutix Corporation
KYORIN Pharmaceutical Co., Ltd.
Lytix Biopharma AS
TAXIS Pharmaceuticals, Inc.
Aureogen Biosciences, Inc.
Cantab Biopharmaceuticals Limited

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.